Pfizer Inc./Protalix BioTherapeutics Inc. are guaranteeing Gaucher disease patients who switch to newly approved Elelyso (taliglucerase alfa) access to a two-year supply of the enzyme replacement therapy to inspire them to switch to the plant-based option from animal-based competitor products that have run into production difficulties.
In addition to the customary patient support for orphan indications, Elelyso (formerly Uplyso) will be launched with a Supply Continuity Program, Vera Wu, Pfizer global asset team lead for Elelyso,...